The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
I think the bigger issue is really as more and more of these drugs become available hopefully it leads to a more and more personalized type of intervention where look if you got somebody who's walking around with a low C reactive protein and a low fibrinogen and their issue is elevated you know LDL P I don't see why you'd want to use an il one agonist on that or antagonist murder on that patient
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.